Earnings Feed
Start Free
RHYTHM PHARMACEUTICALS, INC.·4

Jun 25, 6:06 PM ET

TETRAULT LYNN A. 4

Research Summary

AI-generated summary

Updated

RHYTHM (RYTM) Director Lynn A. Tetrault Exercises Options, Receives RSUs

What Happened

  • Lynn A. Tetrault, a director of Rhythm Pharmaceuticals (RYTM), recorded an exercise/conversion of 4,712 derivative securities on 2026-06-23 (Form 4 shows a matching disposition of 4,712 derivatives at $0). On 2026-06-24 she was granted two restricted stock unit (RSU) awards totaling 6,015 RSUs (3,691 + 2,324) at $0 per unit. The filing reports no cash proceeds or sale prices for the 6/23 disposition.

Key Details

  • Transaction dates: 2026-06-23 (exercise/conversion and reported disposition) and 2026-06-24 (RSU grants).
  • Reported prices/values: exercise/conversion listed with N/A and a reported disposition price of $0; RSU grants at $0 (typical for awards). No cash proceeds are shown.
  • Shares after transaction: the filing does not state total shares owned after these transactions.
  • Relevant footnotes from the filing:
    • F1: Each RSU = contingent right to one share of common stock.
    • F2/F4: Some RSUs are noted as fully vested and/or vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting (footnotes indicate different RSU vesting treatments in the filing).
    • F3: Options referenced vest by the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.
  • Timeliness: Filing date 2026-06-25 for transactions dated 6/23–6/24/2026 — no late filing flagged in the report.

Context

  • The Form 4 records an exercise/conversion of derivative securities (transaction code M) and a corresponding disposition at $0; the filing does not show an open-market sale or cash proceeds, so this appears to be a conversion/transfer event rather than a market sale.
  • The 6,015 RSUs are awards (transaction code A) and represent contingent rights to receive shares; some RSUs in the filing are described as fully vested while others have future vesting conditions per footnotes.
  • Awards and exercises are routine insider events and are not, on their own, a clear buy/sell market signal — purchases (out-of-pocket buys) tend to carry more informational weight for investors.